Phase 2 trial shows promise for non-small cell lung cancer treatment

Results from the phase 2 MDT-BRIDGE trial, published in Nature Medicine on October 27, 2026, indicate positive outcomes for neoadjuvant durvalumab plus platinum-based chemotherapy in patients with resectable or borderline resectable non-small cell lung cancer. Beyond the clinical findings, the trial's structured multidisciplinary tumor board reassessment protocol is noted for formalizing adaptive decision-making in surgical oncology, potentially improving patient care pathways.